Financial Performance Expectations - The company expects a net profit of -25,000.00 million yuan for the year 2025, compared to a net profit of 2,657.49 million yuan in the same period last year[3] - Projected operating revenue for 2025 is 550,000.00 million yuan, a decrease from 600,000.00 million yuan in the previous year[3] - The net profit attributable to shareholders is expected to be -25,000.00 million yuan, reflecting a significant decline from the previous year's profit[3] Factors Affecting Performance - The decline in performance is attributed to increased competition and changes in consumer habits within the chain pharmacy industry[5] - The company has conducted impairment testing on goodwill related to acquired subsidiaries, leading to significant asset impairment losses impacting current profits[6] - The earnings forecast reflects the company's response to macroeconomic changes and industry policy adjustments[5] Financial Reporting and Auditing - The financial data presented in the earnings forecast has not been audited by external auditors[4] - The company advises investors to exercise caution and consider investment risks based on preliminary financial estimates[7] - The earnings forecast is based on initial calculations by the company's finance department and will be finalized in the 2025 annual report[7] - The company has communicated with its auditing firm regarding the earnings forecast, with no discrepancies reported[4]
达嘉维康(301126) - 2025 Q4 - 年度业绩预告